Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine August 2024, 65 (8) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: Heinrich Schelbert, a pioneer in assessment of cardiac function and a past JNM editor-in-chief, talks with Heiko Schoder and Johannes Czernin about his long career in nuclear medicine.

Page 1163

Effects of 177Lu dose conversion method: Brosch-Lenz and members of the SNMMI 177Lu dosimetry challenge continue their evaluation of sources contributing to variability in dosimetry workflow and calculation of absorbed dose.

Page 1166

Ending the LNT model: Doss explores factors contributing to the persistence of the linear no-threshold model and offers a suggestion for resolving this contentious and long-standing issue.

Page 1173

Radioembolization of NENs: Watanabe and colleagues report on the potential of multicompartment dosimetry in 90Y glass microsphere radioembolization of neuroendocrine neoplasms, observing higher response rates and longer progression-free survival with higher doses.

Page 1175

Posttreatment PET/CT in HNSCC: Clement and colleagues evaluate the diagnostic performance of 18F-FDG PET/CT in detecting subclinical recurrence over a 5-y period after treatment for head and neck squamous cell carcinoma.

Page 1181

68Ga-FAPI46 in mesothelioma: Kessler and colleagues characterize the association of histopathologic FAP expression and 68Ga-FAPI46 PET uptake in malignant mesothelioma and compare resulting sensitivity, specificity, positive/negative predictive values, and detection rates with those of 18F-FDG PET/CT and contrast-enhanced CT.

Page 1188

PET/CT and prognosis in anal cancer: Combet-Curt and colleagues document the predictive value of 18F-FDG PET/CT in terms of recurrence-free, colostomy-free, and overall survival after radiation therapy of squamous cell carcinoma of the anus, including baseline and posttherapeutic imaging.

Page 1194

PRECISE-MDT study: Bauckneht and colleagues assess the impact of different imaging modalities on guidance of metastasis-directed therapy and resulting effects on oncologic outcomes within a large, multiinstitutional cohort of patients with oligorecurrent prostate cancer.

Page 1202

PSMA PET with HOXB13 profiling: Angappulige and colleagues investigate whether SUVs on PSMA PET correlate with expression of Homeobox 13, an oncogenic transcription factor that promotes resistance to androgen receptor–targeted therapies in prostate cancer.

Page 1210

FAP in glioblastoma and gliosarcoma: Oster and colleagues explore the clinical relevance of FAP expression in gliosarcoma and glioblastoma and the diagnostic and therapeutic implications of the ways in which this expression correlates with 68Ga-FAP inhibitor–46 PET uptake.

Page 1217

SIRT AD and spatial liver function: Lu and colleagues identify correlations between 90Y PET absorbed dose voxel maps and nontumoral changes in regional liver function derived from dynamic MRI before and after selective internal radiation therapy.

Page 1224

VIOLET trial protocol: Buteau and colleagues report on a planned phase I/II trial to determine whether [161Tb]Tb-PSMA-I&T can deliver effective radiation to sites of metastatic prostate cancer with an acceptable safety profile.

Page 1231

[18F-Flotufolastat PET/CT reader agreement: Kuo and colleagues document inter- and intrareader reproducibility of 18F-flotufolastat PET/CT scans from 2 phase 3 studies in patients with newly diagnosed and recurrent prostate cancer.

Page 1239

Biomarker for 177Lu-DOTATATE–induced leukopenia: Steinhelfer and colleagues identify spleen volume reduction as a reliable and independent predictor of long-term leukopenia risk after peptide receptor radionuclide therapy.

Page 1244

Radiopharmaceuticals targeting NTSR-1: Fonseca Cabrera and colleagues use multiamine macrocyclic moieties as linkers or chelators in theranostic tracers targeting the neurotensin receptor-1, with a goal of achieving elevated tumor uptake, minimal background interference, and prolonged tumor retention.

Page 1250

FAP-targeted radiopharmaceutical therapy: Mukkamala and colleagues detail the design, development, and preclinical evaluation of a new FAP-targeted radioligand incorporating optimal features of 3 previous therapies and offering high tumor–to–healthy-tissue ratios.

Page 1257

Metaanalysis of [177Lu]Lu-PSMA dosimetry: Ells and colleagues conduct a systematic review and metaanalysis comparing dosimetry methods for the most frequently used [177Lu]Lu-PSMA radiopharmaceutical therapy compounds.

Page 1264

STP [177Lu]Lu-PSMA dosimetry: Resch and colleagues compare different single-time-point approaches in radionuclide therapy dosimetry using multiple-time-point protocols as references and call for greater standardization to facilitate reliable STP dosimetry.

Page 1272

Myocardial somatostatin PET uptake: Larive and colleagues research factors associated with detection of myocardial uptake on somatostatin PET scans recorded for oncology indications and differential PET criteria that characterize myocardial uptake in acute myocarditis patients.

Page 1279

[18F]MFBG LAFOV PET/CT in neuroblastoma: Borgwardt and colleagues detail experience with a long-axial-field-of-view PET/CT system and this new tracer in children with neuroblastoma, noting shorter scan times, higher sensitivity, and avoidance of general anesthesia or sedation.

Page 1286

Noninvasive imaging of olfaction: Adilbay and colleagues describe preclinical and human tissue studies on the use of Tsp1a-IR800P, a novel fluorescent probe, as a tool to diagnose loss of smell by selectively targeting NaV1.7 expression in olfactory epithelium.

Page 1293

Bimodal guidance in hepatobiliary surgery: Rietbergen and colleagues summarize development and preclinical studies with 99mTc-hHEPATO-Cy5, a bimodal tracer that facilitates both fluorescence guidance and radioguidance in surgical resection of deep hepatic lesions.

Page 1301

“Explainable” radiomics: Captier and colleagues introduce a model- and modality-agnostic tool that explains predictions of multiregion radiomic models by highlighting the contribution of each individual region.

Page 1307

HMC algorithm for uMI Panorama: Kang and colleagues validate Neurofocus, a head motion–correction algorithm for the uMI Panorama PET/CT system, using a data-driven, statistics-based approach.

Page 1313

NeuroEXPLORER performance: Li and colleagues provide the physical characteristics, performance evaluation, and first human images with the NeuroEXPLORER, a dedicated brain PET imager with high spatial resolution, high sensitivity, and a 3D camera for markerless continuous motion tracking.

Page 1320

Off-target effects of enzalutamide: Bauckneht and colleagues compare brain metabolism in patients with metastatic castration-resistant prostate cancer with and without enzalutamide treatment.

Page 1327

False-positive FAPI PET after therapy: Ludwig and colleagues offer an illustrative case study in a patient with lingering [68Ga]Ga-FAPI uptake in postchemotherapy fibronecrotic tissue and urge caution in interpretation of posttherapy residual lesions.

Page 1328

  • © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (8)
Journal of Nuclear Medicine
Vol. 65, Issue 8
August 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Aug 2024, 65 (8) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Aug 2024, 65 (8) 6A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire